Sociodemographic and clinicopathologic characteristics of patients treated with high dose rate prostate brachytherapy in Nigeria.

IF 1.2 Q4 ONCOLOGY
ecancermedicalscience Pub Date : 2024-08-14 eCollection Date: 2024-01-01 DOI:10.3332/ecancer.2024.1740
Abbas A Abdus-Salam, Mutiu A Jimoh, Ayorinde M Folasire, Atara I Ntekim, Olabisi T Ojo, Chiamaka G Ehiedu, Sikiru A Yusuf, Augustine O Takure, Bidemi I Akinlade, Olusola K Idowu, Afolabi A Oladeji, Foluke O Sarimiye, Adeniyi A Adenipekun
{"title":"Sociodemographic and clinicopathologic characteristics of patients treated with high dose rate prostate brachytherapy in Nigeria.","authors":"Abbas A Abdus-Salam, Mutiu A Jimoh, Ayorinde M Folasire, Atara I Ntekim, Olabisi T Ojo, Chiamaka G Ehiedu, Sikiru A Yusuf, Augustine O Takure, Bidemi I Akinlade, Olusola K Idowu, Afolabi A Oladeji, Foluke O Sarimiye, Adeniyi A Adenipekun","doi":"10.3332/ecancer.2024.1740","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Prostate cancer is the most commonly diagnosed malignancy in adult males. High dose rate brachytherapy (HDRB) recently became available in the country for the management of localized prostate cancer in addition to other treatment modalities. HDRB offers a less invasive option to radical prostatectomy and also has a better side effects profile.</p><p><strong>Aim: </strong>To report the socio-demographic features of the patients treated with HDRB, the clinicopathologic pattern of their disease and possible predictors of these features.</p><p><strong>Methods: </strong>A retrospective study of patients with histopathologically confirmed prostate cancer, who had HDRB at the Department of Radiation Oncology, University College Hospital, Ibadan, Nigeria, between July 2020 and 2023 was done. Patients' socio-demographic and clinicopathologic characteristics were extracted from their treatment records.</p><p><strong>Results: </strong>A total of 73 patients had HDRB within the period under review. The median age was 66 years (51-78 years). About 40% had prostate cancer diagnosed following routine prostate-specific antigen (PSA) screening. The median screening PSA was 20.5 ng/mL (5.83-75.35 ng/mL). About a quarter (24.7%) were asymptomatic at presentation while frequency (60.3%), nocturia (45.2%) and urgency (35.6%) were the most common symptoms. The median initial PSA was 26.00 ng/mL (5.10-124.50 ng/mL) and the median PSA before brachytherapy was 6.25 ng/mL (0.03-175.30 ng/mL), the majority (75.3%) had androgen deprivation therapy before brachytherapy. Forty-seven patients (64.4%) presented with TNM stages 1 and 2 while grade group 2 (24.7%) and high risk (76.7%) were the commonest grade group and risk group, respectively. There was a significant association between age group and TNM stage (<i>p</i> = 0.043), level of education (LOE) and TNM stage (<i>p</i> = 0.037) as well as PSA screening and grade group (<i>p</i> = 0.007).</p><p><strong>Conclusion: </strong>The majority of the patients who presented for prostate brachytherapy were elderly, had higher initial PSA, were in the high-risk group and had early-stage disease. About 25% of the patients were asymptomatic at presentation. Patients with tertiary LOE and elderly patients presented more with stage 1 and 2 diseases.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1740"},"PeriodicalIF":1.2000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11484653/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2024.1740","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Prostate cancer is the most commonly diagnosed malignancy in adult males. High dose rate brachytherapy (HDRB) recently became available in the country for the management of localized prostate cancer in addition to other treatment modalities. HDRB offers a less invasive option to radical prostatectomy and also has a better side effects profile.

Aim: To report the socio-demographic features of the patients treated with HDRB, the clinicopathologic pattern of their disease and possible predictors of these features.

Methods: A retrospective study of patients with histopathologically confirmed prostate cancer, who had HDRB at the Department of Radiation Oncology, University College Hospital, Ibadan, Nigeria, between July 2020 and 2023 was done. Patients' socio-demographic and clinicopathologic characteristics were extracted from their treatment records.

Results: A total of 73 patients had HDRB within the period under review. The median age was 66 years (51-78 years). About 40% had prostate cancer diagnosed following routine prostate-specific antigen (PSA) screening. The median screening PSA was 20.5 ng/mL (5.83-75.35 ng/mL). About a quarter (24.7%) were asymptomatic at presentation while frequency (60.3%), nocturia (45.2%) and urgency (35.6%) were the most common symptoms. The median initial PSA was 26.00 ng/mL (5.10-124.50 ng/mL) and the median PSA before brachytherapy was 6.25 ng/mL (0.03-175.30 ng/mL), the majority (75.3%) had androgen deprivation therapy before brachytherapy. Forty-seven patients (64.4%) presented with TNM stages 1 and 2 while grade group 2 (24.7%) and high risk (76.7%) were the commonest grade group and risk group, respectively. There was a significant association between age group and TNM stage (p = 0.043), level of education (LOE) and TNM stage (p = 0.037) as well as PSA screening and grade group (p = 0.007).

Conclusion: The majority of the patients who presented for prostate brachytherapy were elderly, had higher initial PSA, were in the high-risk group and had early-stage disease. About 25% of the patients were asymptomatic at presentation. Patients with tertiary LOE and elderly patients presented more with stage 1 and 2 diseases.

尼日利亚接受高剂量率前列腺近距离治疗患者的社会人口学和临床病理学特征。
简介前列腺癌是成年男性最常见的恶性肿瘤。最近,除了其他治疗方式外,高剂量率近距离放射治疗(HDRB)也开始在国内用于治疗局部前列腺癌。目的:报告接受高剂量近距离放射治疗的患者的社会人口学特征、临床病理学模式以及这些特征的可能预测因素:对 2020 年 7 月至 2023 年期间在尼日利亚伊巴丹大学学院医院放射肿瘤科接受 HDRB 治疗的组织病理学确诊前列腺癌患者进行回顾性研究。研究人员从患者的治疗记录中提取了患者的社会人口学特征和临床病理学特征:在审查期间,共有 73 名患者接受了 HDRB 治疗。中位年龄为 66 岁(51-78 岁)。约 40% 的前列腺癌患者是在常规前列腺特异性抗原 (PSA) 筛查后确诊的。筛查PSA的中位数为20.5纳克/毫升(5.83-75.35纳克/毫升)。约四分之一(24.7%)的患者在就诊时无症状,而尿频(60.3%)、夜尿(45.2%)和尿急(35.6%)是最常见的症状。初始PSA中位数为26.00纳克/毫升(5.10-124.50纳克/毫升),近距离治疗前PSA中位数为6.25纳克/毫升(0.03-175.30纳克/毫升),大多数患者(75.3%)在近距离治疗前接受了雄激素剥夺治疗。47名患者(64.4%)的TNM分期为1期和2期,而2级组(24.7%)和高危组(76.7%)分别是最常见的等级组和风险组。年龄组与TNM分期(P = 0.043)、受教育程度(LOE)与TNM分期(P = 0.037)以及PSA筛查与分级组(P = 0.007)之间存在明显关联:结论:大多数前来接受前列腺近距离放射治疗的患者都是老年人,初始PSA较高,属于高危人群,疾病处于早期。约25%的患者在就诊时无症状。患有三级LOE的患者和老年患者多为1期和2期疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
5.60%
发文量
138
审稿时长
27 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信